Long-Term Data Reinforce Givinostat Efficacy, Safety in DMD
Givinostat shows promise in delaying Duchenne muscular dystrophy (DMD) progression, enhancing mobility, and maintaining safety in long-term treatment.
Previous Post
ART Adherence Linked to Patient-Centered Care From Patient-Provider Relationships
Next Post
DUOS Survey: Americans Lack Confidence in Medicare/Medicaid and Face Economic Hardship
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago